Finance

Lists
Why is CRL up 5,14%?
Dive Deeper
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
US$315,45
+5,14%
(+15,43) 1D
US$315,45
0,00% (0,00)
After hours
Closed: 20 ຕ.ລ., 16 ໂມງ 0 ນາທີ 07 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
US$308,84
High
US$317,59
Low
US$304,00
Mkt. cap
15,06 ຕື້
Avg. vol.
971,54 ພັນ
Volume
1,27 ລ້ານ
52-wk high
US$333,30
52-wk low
US$146,20
EPS
US$-4,85
Beta
1,40
Shares outstanding
47,74 ລ້ານ
No. of employees
19 ພັນ
Open
US$308,84
High
US$317,59
Low
US$304,00
Mkt. cap
15,06 ຕື້
Avg. vol.
971,54 ພັນ
Volume
1,27 ລ້ານ
52-wk high
US$333,30
52-wk low
US$146,20
EPS
US$-4,85
Beta
1,40
Shares outstanding
47,74 ລ້ານ
No. of employees
19 ພັນ
News stories
From web sources and news partners
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees19 ພັນ
Founded1947
HeadquartersWilmington, ມາຊາຊູເຊັດ, ສະຫະລັດ
SectorHealth care
Websitecriver.com
Analyst ratings
Based on 15 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
14
Hold
1
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current US$315,45
US$357,00 (+13,17%)
Average
US$329,85 (+4,56%)
Lowest
US$295,00 (-6,48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Casey Woodring
J.P. Morgan
Buy
Maintained
US$345,00
+9,4%
10/16/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
US$340,00
+7,8%
10/13/2026
Ryan Halsted
RBC Capital
Buy
Maintained
US$322,00
+2,1%
10/06/2026
Kevin Caliendo
UBS
Buy
Initiated
US$357,00
+13,2%
09/30/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
US$340,00
+7,8%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
US$320,00
+1,4%
09/25/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
US$330,00
+4,6%
09/25/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
US$295,00
-6,5%
09/25/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
US$334,00
+5,9%
09/25/2026
Luke Sergott
Barclays
Buy
Maintained
US$330,00
+4,6%
09/24/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
US$325,00
+3%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
US$320,00
+1,4%
09/22/2026
David Toung
Argus Research
Buy
Reiterated
US$330,00
+4,6%
09/16/2026
Michael Luo CFA
CLSA
Hold
Downgraded
US$219,00
-30,6%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
US$265,00
-16%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
US$215,00
-31,8%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
US$175,00
-44,5%
02/25/2026
Last report
5 ສ.ຫ. 2026
Fiscal period
Q2 2026
US$3,02 / US$2,74
+10,31%beat
Revenue / Est. (USD)
1,00 ຕື້ / 977,20 ລ້ານ
+2,75%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
1,00 ຕື້
994,23 ລ້ານ
995,83 ລ້ານ
1,00 ຕື້
Cost of goods sold
652,72 ລ້ານ
665,36 ລ້ານ
672,79 ລ້ານ
625,06 ລ້ານ
Cost of revenue
652,72 ລ້ານ
665,36 ລ້ານ
672,79 ລ້ານ
625,06 ລ້ານ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
173,64 ລ້ານ
192,02 ລ້ານ
149,12 ລ້ານ
214,18 ລ້ານ
Operating expense
201,05 ລ້ານ
284,04 ລ້ານ
164,46 ລ້ານ
227,27 ລ້ານ
Total operating expenses
853,77 ລ້ານ
949,40 ລ້ານ
837,25 ລ້ານ
852,33 ລ້ານ
Operating income
151,08 ລ້ານ
44,83 ລ້ານ
158,58 ລ້ານ
151,74 ລ້ານ
Other non operating income
-22,62 ລ້ານ
27,72 ລ້ານ
-123,11 ລ້ານ
25,99 ລ້ານ
EBT including unusual items
87,20 ລ້ານ
-294,10 ລ້ານ
-29,94 ລ້ານ
53,17 ລ້ານ
EBT excluding unusual items
104,48 ລ້ານ
35,18 ລ້ານ
8,62 ລ້ານ
148,43 ລ້ານ
Income tax expense
31,64 ລ້ານ
-17,81 ລ້ານ
-15,14 ລ້ານ
53,93 ລ້ານ
Effective tax rate
36,29%
6,06%
50,56%
101,43%
Other operating expenses
-
-
-
-
Net income
54,42 ລ້ານ
-276,56 ລ້ານ
-14,84 ລ້ານ
-1,48 ລ້ານ
Net profit margin
5,42%
-27,82%
-1,49%
-0,15%
Earnings per share
2,43
2,39
2,06
3,02
Interest and investment income
1,42 ລ້ານ
1,02 ລ້ານ
1,03 ລ້ານ
1,03 ລ້ານ
Interest expense
-25,40 ລ້ານ
-23,78 ລ້ານ
-26,74 ລ້ານ
-30,34 ລ້ານ
Net interest expenses
-23,98 ລ້ານ
-22,76 ລ້ານ
-25,71 ລ້ານ
-29,31 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
236,25 ລ້ານ
169,61 ລ້ານ
225,73 ລ້ານ
217,54 ລ້ານ
Gain or loss from assets sale
-
-
117,98 ລ້ານ
24,92 ລ້ານ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
ແອັບຂອງ Google